Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Total Non-Current Liabilities came in at $2.2 billion in Q2 2026, down 2.57% on a YoY basis from $2.2 billion in Q2 2025, and up 1.53% quarter-over-quarter from $2.1 billion in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has reported Total Non-Current Liabilities for 5 consecutive years, with $2.2 billion the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Non-Current Liabilities fell 2.57% year-over-year to $2.2 billion; the trailing twelve-month figure through Jun 2026 stood at $2.2 billion (down 2.57% YoY), and the FY2025 full-year result was $2.1 billion, down 3.14% from the prior year.
- Total Non-Current Liabilities advanced to $2.2 billion in Q2 2026 per FTRE's latest filing, from $2.1 billion in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.6 billion in Q1 2024 and bottomed at $923.6 million in Q4 2022.
- Historically, Total Non-Current Liabilities has averaged $2.2 billion across 5 years, with a median of $2.2 billion in 2024.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities surged 180.03% in 2023, then retreated 19.21% in 2024.
- Over 5 years, Total Non-Current Liabilities stood at $923.6 million in 2022, then soared by 180.03% to $2.6 billion in 2023, then declined by 15.65% to $2.2 billion in 2024, then declined by 3.14% to $2.1 billion in 2025, then increased by 1.86% to $2.2 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $2.2 billion, $2.1 billion, and $2.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn | 22.94 Bn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 1.56 Bn |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn | 4.24 Bn |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn | 6.94 Bn |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | 2.15 Bn |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - | 30.49 Mn |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn | 553.39 Mn |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn | 22.91 Mn |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn | - |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.15 Bn |
| Mar 31, 2026 | 2.12 Bn |
| Dec 31, 2025 | 2.11 Bn |
| Sep 30, 2025 | 2.12 Bn |
| Jun 30, 2025 | 2.21 Bn |
| Mar 31, 2025 | 2.23 Bn |
| Dec 31, 2024 | 2.18 Bn |
| Sep 30, 2024 | 2.11 Bn |
| Jun 30, 2024 | 2.07 Bn |
| Mar 31, 2024 | 2.62 Bn |
| Dec 31, 2023 | 2.59 Bn |
| Sep 30, 2023 | 2.59 Bn |
| Jun 30, 2023 | 2.57 Bn |
| Dec 31, 2022 | 923.60 Mn |